URGNUroGen Pharma Ltd.Finished
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
Bladder Cancer · Urothelial Carcinoma · Urothelial Carcinoma Bladder
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +5.1
2 insiders sold shares within a month
Since Sep 8, 2026 · was worth 10, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 99 (final count)
- Started
- Aug 29, 2024
- Main results expected
- Sep 11, 2025
- Fully finished
- Sep 15, 2026
- Results posted
- Sep 28, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Complete Response Rate (CRR)
Measured over: 3 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 5.1, since 2026-09-08, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06331299 · record last updated 2026-10-22 · checked 2026-11-09 15:47 UTC